RCEL
AVITA Medical, Inc.
$4.16
-0.48%
$128.0M
No data for this timeframe.
Vol
Market Cap$128.0M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders6 funds
Inst. Value$5.8M
Inst. Activity2 buys / 1 sells
Insider Activity8B / 0S
Insider Net $$122.2K
Reddit Sentiment33° Cool
SEC Reports2
Press Releases2
Exchange OTC·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001762303·Prev Close $4.18
Recent Activity
Jun 9, 2026
Insider
Woody Joseph Fralin bought 5,000 shares
Director @ $4.20 ($21.0K)
Jun 3, 2026
Insider
Woody Joseph Fralin bought 5,000 shares
Director @ $4.10 ($20.5K)
Jun 2, 2026
Insider
Woody Joseph Fralin bought 5,000 shares
Director @ $4.18 ($20.9K)
May 17, 2026
SEC
AVITA Medical reported Q1 2026 EPS of -$0.35, beating consensus by 14.2%. Revenue was not disclosed in this brief releas
PRESS-RELEASE — Impact 5/10
May 17, 2026
earnings
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical to host separate investor webinar and Melbourne Q&A event following Q1 2026 results an
Apr 23, 2026
SEC
AVITA Medical announced it will report Q1 2026 financial results on May 14, 2026, with a conference call to follow. No f
PRESS-RELEASE — Impact 3/10
Inst.
MORGAN STANLEY — ADD
149,715 shares ($516.5K)
Inst.
BANK OF AMERICA CORP — TRIM
25,329 shares ($87.4K)
Price Targets
$7.06
+71.4% upside
Strong Buy
Current $4.12
Low $5.35
Median $5.89
High $9.94
3 analysts
$5.35
$9.94
Analyst Ratings
3Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 15, 2026 | Lake Street | UPGRADE | Hold → Buy |
| Apr 9, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
| Mar 5, 2026 | Northland Capital Markets | INITIATE | Outperform |
| Feb 17, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.41 ▼ -11.5% | $-0.49 — $-0.31 | 30% YoY | 5 |
| Next Q | $-0.38 ▼ -25.6% | $-0.46 — $-0.27 | 46% YoY | 5 |
| Current FY | $-1.55 ▼ -19.5% | $-1.92 — $-0.94 | 37% YoY | 5 |
| Next FY | $-1.14 ▼ -303.8% | $-2.34 — $0.18 | 26% YoY | 5 |
Latest Reports
BULLISH
PRESS-RELEASE
5/10
AVITA Medical reported Q1 2026 EPS of -$0.35, beating consensus by 14.2%. Revenue was not disclosed in this brief releas
May 17, 2026
NEUTRAL
Press
3/10
AVITA Medical appointed interim CEO Cary Vance as permanent President and CEO, and elevated Jan Stern Reed to Board Chai
Apr 30, 2026
NEUTRAL
PRESS-RELEASE
3/10
AVITA Medical announced it will report Q1 2026 financial results on May 14, 2026, with a conference call to follow. No f
Apr 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $5.0M | — |
| MORGAN STANLEY | $516.5K | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $159.6K | TRIM |
| BANK OF AMERICA CORP | $87.4K | TRIM |
| WELLS FARGO & COMPANY/MN | $65.0K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 9, 2026 | Woody Joseph | BUY | $21.0K |
| Jun 3, 2026 | Woody Joseph | BUY | $20.5K |
| Jun 2, 2026 | Woody Joseph | BUY | $20.9K |
| Jun 1, 2026 | Woody Joseph | BUY | $21.7K |
| May 29, 2026 | O'Toole David | A | $15.3K |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
6 institutional holders with $5.8M total value (1,687,365 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,444,579 | $5.0M | 85.6% | — |
| 2 | MORGAN STANLEY | 149,715 | $516.5K | 8.9% | ADD +54.0% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 46,255 | $159.6K | 2.7% | TRIM -46.8% |
| 4 | BANK OF AMERICA CORP /DE/ | 25,329 | $87.4K | 1.5% | TRIM -59.2% |
| 5 | WELLS FARGO & COMPANY/MN | 18,832 | $65.0K | 1.1% | ADD +98.5% |
| 6 | FMR LLC | 2,655 | $9.2K | 0.2% | TRIM -38.1% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 97,242 | 149,715 | +54.0% | $516.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 62,139 | 25,329 | -59.2% | $87.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 9,487 | 18,832 | +98.5% | $65.0K | 2025-Q4 |
| MORGAN STANLEY | TRIM | 222,193 | 97,242 | -56.2% | $496.9K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 409,799 | 75,400 | -81.6% | $385.3K | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | TRIM | 85,817 | 45,634 | -46.8% | $233.2K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 15,727 | 9,487 | -39.7% | $48.5K | 2025-Q3 |
| FMR LLC | TRIM | 4,586 | 2,840 | -38.1% | $14.5K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 88,013 | 222,193 | +152.5% | $1.2M | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 64,215 | 85,817 | +33.6% | $454.0K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | ADD | 41,784 | 62,551 | +49.7% | $330.9K | 2025-Q2 |
| UBS Group AG | DOUBLED | 128,630 | 344,728 | +168.0% | $2.8M | 2025-Q1 |
| UBS Group AG | DOUBLED | 17,806 | 128,630 | +622.4% | $1.6M | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 89,682 | 62,219 | -30.6% | $796.4K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 9,871 | 13,941 | +41.2% | $178.4K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 70,905 | — | $760.1K | 2024-Q3 |
8 unique insiders with 8 transactions. Net insider value: $122.2K ($122.2K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 9, 2026 | Woody Joseph Fralin | Director | BUY | 5,000 | $4.20 | $21.0K |
| Jun 3, 2026 | Woody Joseph Fralin | Director | BUY | 5,000 | $4.10 | $20.5K |
| Jun 2, 2026 | Woody Joseph Fralin | Director | BUY | 5,000 | $4.18 | $20.9K |
| Jun 1, 2026 | Woody Joseph Fralin | Director | BUY | 5,000 | $4.34 | $21.7K |
| May 29, 2026 | O'Toole David D | CFO | A | 5,000 | $3.05 | $15.3K |
| May 29, 2026 | Vance Cary Guy | President and CEO | A | 5,000 | $3.05 | $15.3K |
| May 20, 2026 | O'Toole David D | CFO | BUY | 2,000 | $4.26 | $8.5K |
| May 19, 2026 | O'Toole David D | CFO | BUY | 2,000 | $4.24 | $8.5K |
| Mar 11, 2026 | O'Toole David D | CFO | BUY | 1,800 | $4.78 | $8.6K |
| Feb 19, 2026 | O'Toole David D | CFO | BUY | 3,000 | $4.15 | $12.5K |
| Jan 20, 2026 | McNamara Robert | Director | A | 16,133 | $0.00 | $0.00 |
| Jan 20, 2026 | McNamara Robert | Director | A | 22,214 | $0.00 | $0.00 |
| Jan 20, 2026 | Woody Joseph Fralin | Director | A | 16,133 | $0.00 | $0.00 |
| Jan 20, 2026 | Woody Joseph Fralin | Director | A | 22,214 | $0.00 | $0.00 |
| Jan 20, 2026 | Tarnoff Michael E | Director | A | 16,133 | $0.00 | $0.00 |
| Jan 20, 2026 | Tarnoff Michael E | Director | A | 22,214 | $0.00 | $0.00 |
| Jan 20, 2026 | COOK JEREMY CURNOCK | Director | A | 16,133 | $0.00 | $0.00 |
| Jan 20, 2026 | COOK JEREMY CURNOCK | Director | A | 22,214 | $0.00 | $0.00 |
| Jan 20, 2026 | Crowe Suzanne | Director | A | 16,133 | $0.00 | $0.00 |
| Jan 20, 2026 | REED JAN STERN | Director | A | 22,214 | $0.00 | $0.00 |
| Jan 20, 2026 | REED JAN STERN | Director | A | 16,133 | $0.00 | $0.00 |
| Jan 20, 2026 | Crowe Suzanne | Director | A | 22,214 | $0.00 | $0.00 |
| Jan 5, 2026 | Woody Joseph Fralin | Director | A | 29,446 | $0.00 | $0.00 |
| Jan 5, 2026 | Woody Joseph Fralin | Director | A | 40,547 | $0.00 | $0.00 |
| Aug 6, 2025 | Tarnoff Michael E | Director | A | 26,250 | $0.00 | $0.00 |
| Aug 6, 2025 | Tarnoff Michael E | Director | A | 19,063 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 4.0/10.
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 3 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.06 mean target
+71.4% upside
Strong Buy (1.50)
$5.35 Low
$9.94 High
| Metric | Value |
|---|---|
| Current Price | $4.12 |
| Target Low | $5.35 |
| Target Mean | $7.06 |
| Target Median | $5.89 |
| Target High | $9.94 |
| # Analysts | 3 |
| Recommendation | Strong Buy (1.50) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.41 | $-0.49 | $-0.31 | 30.1% | -11.5% | 0↑ 1↓ | $0.0B | -1.8% | 5 |
| Next Q 2026-09-30 |
$-0.38 | $-0.46 | $-0.27 | 46.5% | -25.6% | 0↑ 1↓ | $0.0B | 10.1% | 5 |
| Current FY 2026-12-31 |
$-1.55 | $-1.92 | $-0.94 | 36.8% | -19.5% | 1↑ 2↓ | $0.1B | 14.6% | 5 |
| Next FY 2027-12-31 |
$-1.14 | $-2.34 | $0.18 | 26.3% | -303.8% | — | $0.1B | 28.0% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.409 | |
| 7d ago | $-0.382 | -0.026 |
| 30d ago | $-0.366 | -0.042 |
| 60d ago | $-0.374 | -0.035 |
| 90d ago | $-0.339 | -0.069 |
3 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 15, 2026 | Lake Street | UPGRADE | Hold | Buy |
| Apr 9, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | Northland Capital Markets | INITIATE | — | Outperform |
| Feb 17, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 26, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 16, 2026 | Lake Street | MAINTAIN | Hold | Hold |
| Jan 15, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 3 | 6 | 3 | 0 | 0 | 75% | |
| Apr 1, 2026 | 3 | 6 | 3 | 0 | 0 | 75% | |
| Mar 1, 2026 | 3 | 6 | 3 | 0 | 0 | 75% | |
| Feb 1, 2026 | 3 | 6 | 3 | 0 | 0 | 75% | |
| Jan 1, 2026 | 3 | 6 | 3 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 17, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 17, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
May 17, 2026
earnings
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical to host separate investor webinar and Melbourne Q&A event following Q1 2026 results and business updates.
May 14, 2026
earnings
AVITA Medical Reports First Quarter 2026 Financial Results
AVITA Medical reports Q1 2026 results: $19.3M revenue, improving demand, cost discipline, and progress across its acute wound care platform.
May 14, 2026
earnings_calendar
RCEL Q1 2026 Earnings Scheduled — 2026-05-14
Apr 30, 2026
leadership
AVITA Medical Names Cary Vance as Chief Executive Officer
AVITA Medical appoints Cary Vance as President and CEO following interim tenure; Jan Stern Reed named Board Chair
Apr 23, 2026
earnings
AVITA Medical to Announce First Quarter 2026 Financial Results
AVITA Medical will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026
Apr 15, 2026
other
AVITA Medical Founder Fiona Wood Honored with Lifetime Achievement Award by American Burn Association
AVITA founder Fiona Wood receives ABA Lifetime Achievement Award for pioneering burn care and developing RECELL Spray-On Skin technology
Apr 14, 2026
fda
AVITA Medical Announces Positive Interim Results from Cohealyx® Study Demonstrating Accelerated Time to Skin Grafting
Cohealyx interim data show ~20-day reduction in time to graft vs benchmark, with strong investigator satisfaction and consistent performance across wo
Apr 8, 2026
other
AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness
AVITA Medical Secures 10-Year BARDA Agreement Worth Up to $25.5M to Bolster U.S. Burn Emergency Preparedness
Apr 7, 2026
other
AVITA Medical Showcases Acute Burn and Wound Care Portfolio at ABA 2026, Featuring New Cohealyx Data
AVITA Medical highlights new Cohealyx data and real-world evidence at upcoming ABA 2026, advancing wound healing and improving patient recovery outcom
Apr 6, 2026
government_contract
$26M govt contract: AVITA MEDICAL AMERICAS, LLC
Agency: Department of Health and Human Services. FDA-APPROVED AUTOGRAFT SPARING DEVICE FOR NATIONAL PREPAREDNESS